Zytorvi Toripalimab 240 mg Injection

Zytorvi Toripalimab 240 mg Injection is a humanized monoclonal antibody designed to interfere with the mechanism cancer cells use to "hide" from the immune system. In clinical trials like JUPITER-02, Zytorvi combined with chemotherapy demonstrated a significant increase in progression-free survival (PFS) and overall survival compared to chemotherapy alone. It is now considered a vital tool for oncologists managing aggressive throat and neck cancers.

Why Zytorvi (Toripalimab) is the New Standard

• Targeted PD-1 Blockade: Specifically binds to the PD-1 receptor on T-cells, preventing cancer cells from deactivating the immune response.

• Combination Efficacy: When used with Cisplatin and Gemcitabine, it significantly reduces the risk of disease progression.

• Proven Results in NPC: Unlike broader immunotherapies, Toripalimab has been specifically optimized and approved for Nasopharyngeal Carcinoma.

• Intracranial Activity: Shows promise in managing tumors that are locally advanced or recurrent in the nasopharynx area.

Clinical Administration & Cold-Chain Storage

1. Dosing Regimen: Typically administered as a 240 mg IV infusion every 3 weeks (first-line) or 3 mg/kg every 2 weeks (monotherapy).

2. Infusion Protocol: The first infusion is given over 60 minutes. If well-tolerated, subsequent infusions can be shortened to 30 minutes.

3. Mandatory Refrigeration: Must be stored at 2°C to 8°C (36°F to 46°F) in its original carton to protect it from light.

4. Handling: Do not freeze or shake the vial. The solution should be clear to slightly opalescent.